Evidence map›Paper›PMID 31462593›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Glucose-responsive Insulinoma with Insulin Hypersecretion Suppressed by Metformin.

Kunihisa Hamano, Kayo Akita, Yoko Takeuchi, Tetsuya Suwa, Jun Takeda, Shuji Dodo

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. A Novel Peptide COXCurrent protein & peptide science · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Kunihisa HamanoDivision of Nephrology and Diabetology, Narita Memorial Hospital (Meiyokai Medical Corporation), Japan.
Kayo AkitaDepartment of Thyroidology and Diabetes, Japanese Red Cross Gifu Hospital, Japan.
Yoko TakeuchiDivision of Nephrology and Diabetology, Narita Memorial Hospital (Meiyokai Medical Corporation), Japan.
Tetsuya SuwaDepartment of Immunity and Endocrinology Internal Medicine, Gifu University Hospital, Japan.
Jun TakedaKoseikai Takeda Hospital, Japan.
Shuji DodoDivision of Nephrology and Diabetology, Narita Memorial Hospital (Meiyokai Medical Corporation), Japan.
Kishokai Medical Corporation · JPGifu Red Cross Hospital · JPGifu University Hospital · JPIjinkai Takeda General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In type 2 diabetes mellitus, metformin suppresses excessive insulin secretion in relation to the intake of glucose. We herein report the case of a 45-year-old man with glucose-responsive insulinoma whose responsive hypoglycemia was alleviated by metformin. The patient had a history of a postprandial loss of consciousness, resulting in hospital admission. He refused surgery and diazoxide administration. A 75-g oral glucose tolerance test after metformin administration revealed the suppression of glucose-responsive insulin hypersecretion and responsive hypoglycemia. Pancreatic head duodenectomy was performed, which alleviated the symptoms. Metformin administration in patients with glucose-responsive insulinoma may therefore be effective for preventing responsive hypoglycemia and hyperinsulinemia.

Indexed as

Glucose Tolerance TestHumansHypoglycemiaHypoglycemic AgentsInsulinInsulinomaMaleMetforminMiddle AgedPancreatic NeoplasmsPostprandial PeriodHypoglycemic AgentsInsulinMetformincase reportinsulinomametforminpostprandialresponsive hypoglycemia

Identifiers

PMID31462593
PMCPMC6949461
OpenAlexW2970599347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.